ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026
Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Unlocking the microbial code: potential role in sarcoidosis pathogenesis and treatment.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac sarcoidosis (CS) is an elusive, yet potentially life-threatening disease marked by granulomatous inflammation of the myocardium, which can lead to arrhythmias, heart failure, and sudden cardiac death. Although corticosteroids have long been the mainstay of treatment, the therapeutic landscape is rapidly evolving. Recent insights have underscored the role of alternative immunosuppressants and biologic agents in enhancing disease control while minimizing long-term toxicity. Advances in imaging, particularly cardiac magnetic resonance (CMR) and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) are transforming both diagnosis and follow-up, enabling earlier detection and personalized monitoring of therapeutic response. At the same time, arrhythmia management and device implantation, especially implantable cardioverter-defibrillators (ICDs), have become central to risk stratification and prevention of fatal outcomes. This review explores the latest developments in the management of CS, highlighting a paradigm shift toward integrated, multidisciplinary care. From immunomodulation to advanced imaging and electrophysiological strategies, we emphasize the importance of tailoring interventions to disease severity and patient risk. Special focus is given to high-risk cases and evolving criteria for heart transplantation, grounded in the most up-to-date clinical evidence.
Indexed as
Identifiers
41474488What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.